Organization Profile

Related Organization(s)

You just read:

New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring's Subcutaneous C1-Esterase Inhibitor in HAE Patients

News provided by

CSL Behring

Apr 04, 2017, 08:00 ET